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The blood-nourishing and hard-softening (BNHS) capsule is a traditional Chinese formula used in the
symptomatic treatment of inflammation and pain. We conducted this randomized controlled trial to
compare the efficacy of BNHS with other commonly prescribed drugs. We recruited 120 patients
from two teaching hospitals; 30 patients in each hospital were randomly assigned to receive BNHS. In
one hospital, the 30 controls were given another traditional Chinese drug; whereas a Western medicine
(chondroprotection drug/Viartril-s) was used as the control in the other hospital. Intervention was carried
out over a period of 4 weeks. Primary outcome measures included self-reported pain level, and changes
in stiffness and functional ability as measured by the Western Ontario McMaster Universities Osteoarth-
ritis (WOMAC) index. Mixed models were used for statistical analysis. Substantial improvements in
disease-specific symptoms were observed, after 4 weeks of treatment, in patients taking BNHS capsules.
As assessed by the WOMAC index, pain level of the BNHS group decreased by 57% [95% confidence
interval (CI) ¼ 50, 63], stiffness by 63% (95% CI ¼ 55, 71) and functional ability increased by 56%
(95% CI ¼ 50, 63). No significant differences were found in any of the outcome measures between
the BNHS group and either of the comparison groups. No severe adverse effects were reported.
However, this study lacked a placebo group; therefore, we conclude that BNHS appears to be as effect-
ive as commonly prescribed medicines for the relief of pain and dysfunction in knee osteoarthritis
patients, but costs a lot less than other Western and herbal drugs in the study.
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Introduction
Osteoarthritis (OA) is the most common joint disease. Clinical
manifestations of OA of the knee are joint pain, stiffness in the
morning or after rest, pain at night, limited joint motion and/or
joint deformity (1). Treatment modalities for knee OA include
non-pharmacologic (e.g. physical and occupational therapy,
aerobic exercise programs, weight control and patient educa-
tion) and pharmacologic therapy [e.g. intra-articular steroid
injections, paracetamol, topical analgesics, non-steroidal
anti-inflammatory drugs (NSAIDs) and opioid analgesics]
(2). Although NSAIDs are the most widely prescribed
drugs to reduce joint pain and stiffness, the inflammatory
component of OA is usually minimal; therefore, the need for
the anti-inflammatory effect of NSAIDs in this condition is
controversial (3). Since the efficacy of NSAIDs in sympto-
matic treatment of OA of the knee depends on analgesic rather
than anti-inflammatory effect, paracetamol has been recently
recommended as the first-line oral drug. On the one hand,
long-term use of paracetamol can lead to hepatic and renal
impairment (4). On the other hand, inhibition of prostaglandin
biosynthesis is directly related to many common and occasion-
ally severe side effects including gastrointestinal bleeding,
hypertension, congestive heart failure, hyperkalemia and renal
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of the risks and benefits of the therapies in comparison with
a less toxic one for OA. Thus, less toxic pain managing proced-
ures, e.g. electroacupuncture or acupuncture as reported, as
well as chondroprotection drugs are considered alternative
treatments and they are widely prescribed in China.
Evidence gathered from a systematic review show that
herbal medicines, which appear relatively safe, may offer
a much-needed alternative, and merit further attention (7).
The blood-nourishing and hard-softening capsule (BNHS),
which is an extract from Bai Shao (radix paeoniae alba), Qin
Jiao (radix gentianae macrophyllae) and Gan Cao (radix gly-
cyrrhizae), containing mainly paconiflorin and gentianine, is
a traditional Chinese herb used for symptomatic treatment of
inflammation and pain in OA. In traditional Chinese medicine
(TCM), OA is known as the Bi syndrome (painful obstruction),
which means either the limbs or the joints are suffered
from pain and malfunction, and herb therapy has long been
a standard treatment. Only limited data are available on the
efficacy and cost-effectiveness of traditional Chinese herbs
in the treatment of OA of the knee. Therefore, we initiated
this study to compare the efficacy of BNHS, another com-
monly prescribed Chinese herb counter osteophytes capsule,
and Western medicine Viartril-s (chondroprotection drug)
in short-term symptomatic treatment of OA of the knee. We
hypothesized that BNHS is as effective as, but will cost less
than, other commonly prescribed drugs chosen for comparison
purposes.
Materials and Methods
Study Design
This was a prospective two-center randomized controlled trial.
All patients underwent a treatment period of 4 weeks, and fol-
lowed for  2 weeks to check for adverse events. The protocol
was approved by the Ethics Committee of the University in
Shanghai. The trial was conducted under the Good Clinical
Practice (GCP) guidelines. All patients gave informed written
consent.
Patients
We screened all outpatients, aged  50, who in 2002 attended
the Department of Orthopaedics in two teaching hospitals
in Shanghai. All of them suffered from painful OA of the
knee according to American College of Rheumatology criteria
(8). Additional inclusion criteria were as follows: intake of
NSAIDs for at least 5 days before the study entry, but pre-
sented with adverse events from previous NSAID therapy;
had pain intensity of  20 mm on the visual analog scales
(VASs) in the previous 48 h when walking on a flat surface;
radiological evidence of OA in the painful joint; at least
grades II–IV on the Kellgren–Lawrence scale on an X-ray
taken within 12 months; and reluctant to continue on pre-
vious drug but willing to change drug treatment. Exclusion
criteria include concurrent medical/arthritic diseases such as
secondary inflammatory arthritis, gout, episodes of acute
monoarticular arthritis, isolated patellofemoral disease, a his-
tory of acute ligamentous or meniscal injury of the study joint
within the previous 2 years and arthroscopy of the affected
knee in the 3 months before the study entry, which could con-
found or interfere with the evaluation of efficacy. Subjects
with hypersensitivity to one of the ingredients of the BNHS
or rescue medication, asthma attacks, episodes of urticaria or
acute rhinitis after administration of aspirin or other NSAIDs
were not included in the study. Patients with severe heart, renal
or liver insufficiency including increased liver function tests,
blood urea nitrogen test, alanine aminotransferase test and
other biochemistry tests three times higher than the upper limit
of normal range, or with acute or suspected gastrointestinal
bleeding, active gastric or duodenal ulcer, ulcer diagnosed
endoscopically within the previous 28 days, steroid injection
<3 months were also excluded.
Procedures
A total of 120 patients, 60 in each hospital, were recruited
from eligible patients. They were randomly (using the sealed
envelope method) and blindly assigned to treatment (BNHS)
or control care (counter osteophytes capsule, another tradi-
tional Chinese drug) in Hospital A. Since Hospital B used
Western medicine (Viartril-s, a chondroprotection drug) as
control care, and there are pharmacokinetical differences
between Chinese and Western medicine, we could only blind
the clinician who performed the assessments.
On Day 0 (Visit 1), patients stopped their previous NSAID
therapy and started taking either BNHS (Experimental) or
counter osteophytes capsule (Control 1) or Viartril-s capsule
(Control 2) with a daily dose of 3.15, 5.25 and 2.25 g, respect-
ively. On Day 14 patients returned for an interim visit (Visit 2).
On Day 28 the final visit took place (Visit 3). Thus, the dura-
tion of treatment was 4 weeks. Two weeks after Visit 3 or after
discontinuation the patient was contacted to check for adverse
events.
As a pain rescue medication, patients were allowed to take
paracetamol 500 mg on demand, e.g. in the event of break-
through pain, with a maximum dose of 4 g day
 1. We counted
and recorded all returned tablets at each visit. There were
no study-specific restrictions with regard to previous and
concomitant medication and treatments, except that
co-administration of NSAIDs was not allowed duringthe study
period. Low-dose aspirin (<100 mg d
 1) was allowed, pro-
vided the dosage was not changed during the study period
and had been stable for months.
Clinical Endpoints and Outcome Measures
The endpoints used for the study included pain when walking
on a flat surface, pain, stiffness and functional ability. To
be specific, the radiological severity of OA was assessed at
Day 0 using the Kellgren–Lawrence index. At each visit
(Days 0, 14 and 28) the patients were rested in a sitting position
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asked to complete the following questionnaires: (i) patient’s
global assessment of treatment satisfaction (5-point scale;
0 ¼ poor, 4 ¼ excellent); (ii) patient’s assessment of pain
when walking on a flat surface (VAS; 0 ¼ no pain, 100 ¼
major pain) (9); (iii) Western Ontario McMaster Universities
Osteoarthritis (WOMAC) LK 3.1; and (iv) global assessment
of treatment response (5-point scale; 0 ¼ very well, 4 ¼ very
very poor) completed by the same investigator (Y.C.).
Tolerability and Safety
Spontaneously reportedadverse events were recorded through-
out the study. Vital signs were monitored at every visit. Labor-
atory investigations including hematology, blood chemistry
and urinalysis were performed at Days 0 and 28, and repeated
on a need basis. For all adverse events the intensity, relation to
test drug and actions taken were recorded.
Statistical Analysis
Data analysis was performed according to the intention-to-
treat (last observation carried forward) principle using SPSS
V12.0. Mixed models, treating group as the between-subject
factor and time as the within-subject factor, were formulated
to compare outcome scores between groups and over time.
When significant interaction between group and time was
detected, analysis of covariance was used to compare groups
at Days 14 and 28 after adjusted for baseline values. While
the overall significance level was set at 0.05, the Sharpened
Bonferroni procedure (10) was used to adjust individual alpha
level when multiple testing was performed.
Results
In the two hospitals, 136 patients were approached before 120
agreed to participate. The primary diagnosis was knee OA. The
radiological Kellgren–Lawrence index was II (slight OA) in
22.5% of the patients and III (moderate OA) or IV (major
OA) in 54.2 and 23.3%, respectively. One hundred sixteen
subjects completed the study per protocol (three experienced
adverse events and one refused to take the study drug, all after
Visit 2), but analyses were carried out usingall the 120 patients
(‘last observation carried forward’ for the four ‘incomplete’
patients). One-third of the randomized participants were males
and the mean age was 69 (SD ¼ 8) years. No significant
differences in mean age or gender ratios were observed
between the BNHS and the control groups (Table 1).
WOMAC
As assessed by the WOMAC index, pain decreased by 57%
[95% confidence interval (CI) ¼ 50, 63; P < 0.001], stiffness
by 63% (95% CI ¼ 55, 71; P < 0.001) and functional ability
increased by 56% (95% CI ¼ 50, 63; P < 0.001) over the
course (i.e. 4 weeks) of the study in BNHS patients. As shown
in Tables 2–4, the improvement from Days 14 to 28 (percent
improvement varied from 33 to 51% depending on the out-
come measure and Hospital) was substantially more than that
from baseline to Week 2 (percent improvement varied from
23 to 32%), although statistical significance was not reached
in some outcome measures among patients in Hospital A.
However, for the sample size we had, we found no signific-
ant differences in the pattern of change from baseline to Day
28 between the treatment and the control groups, regardless
of whether the control was TCM herb or Western medicine,
as none of the interaction terms were significant.
We also noted that although most of the WOMAC scores
(except pain) were significantly different between patients in
the three treatment regimes (i.e. BNHS, Chinese herb control
and Western medicine control) at Day 0, the scores were
very similar at Day 28. This seems to suggest that regardless
of the initial clinical situation of the patient, there is a threshold
such that once the limit is reached the patient cannot improve
further, at least for the drugs used in this study and after
4 weeks of treatment.
Other Outcome Measures
The outcome measures also included assessment of pain when
walking on a flat surface, investigator’s global assessment
of treatment response as well as patient’s global assessment
of treatment satisfaction. The results are shown in Tables 3
and 4. By and large, none of these outcome measures were
significantly different between the BNHS and the control
groups. The patterns of the results for pain when walking on
a flat surface, whether it was the change from baseline to
Weeks 2 or 4, or the absolute scores obtained at end of study,
were very similar to those of the WOMAC scores. However,
patients in the BNHS group in Hospital A appeared to be
slightly more satisfied than the controls (Good/Excellent:
50 versus 30%; P ¼ 0.095), although the differences were
marginally non-significant.
Table 1. Baseline characteristics of the participants
Hospital A (Chinese medicine control) Hospital B (Western medicine control)
BNHS* (n ¼ 30) Counter osteophytes
capsule (n ¼ 30)
P-value BNHS* (n ¼ 30) Viartril-s (n ¼ 30) P-value
Age (years) 59 ± 7 60 ± 10 0.612 64 ± 9 62 ± 9 0.282
Female gender 22 (73.3%) 17 (56.7%) 0.176 24 (80.0%) 17 (56.7%) 0.052
Disease duration (years) 11 ± 8 10 ± 8 0.829 10 ± 8 11 ± 8 0.828
*BNHS ¼ blood-nourishing and hard-softening capsule.
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One BNHS case in Hospital A had macule that could be related
to treatment. Four patients, all in the BNHS group in Hospital
A, withdrew from the trial due to obstipation (one case), gum
swelling (two cases) and bitter feeling in the mouth (one
case). None of these were considered serious by the investi-
gators. No severe adverse cardiovascular events or deep
vein thrombosis were observed. No hospitalization or death
Table 2. Comparison of WOMAC scores between the treatment groups
Baseline
† 2 weeks 4 weeks Percent changed
from baseline
to 4 weeks
Baseline 2 weeks 4 weeks Percent changed
from baseline
to 4 weeks
P-value
z
Hospital A BNHS (n ¼ 30) Counter osteophytes capsule (n ¼ 30)
Total
x (% changed) 24 ± 14 18 ± 11 (29) 11 ± 10 (38) 54 25 ± 12 19 ± 12 (24) 13 ± 10 (32) 48 0.602
Pain
x (% changed) 28 ± 17 21 ± 13 (27) 14 ± 12 (33) 50 29 ± 11 21 ± 11 (28) 15 ± 9 (29) 48 0.753
Stiffness
x (% changed) 26 ± 19 18 ± 17 (23) 12 ± 14 (46)* 54 27 ± 21 20 ± 18 (26) 15 ± 16 (25) 44 0.669
Disability
x (% changed) 23 ± 15 17 ± 12 (28) 11 ± 11 (36) 52 24 ± 14 18 ± 13 (25) 13 ± 11 (33) 46 0.626
Hospital B BNHS (n ¼ 30) Viartril-s (n ¼ 30)
Total
x (% changed) 32 ± 4 22 ± 4 (32) 12 ± 5 (45)** 63 34 ± 6 23 ± 5 (32) 13 ± 5 (43) 62 0.208
Pain
x (% changed) 29 ± 5 20 ± 4 (30) 11 ± 5 (46)** 62 34 ± 8 24 ± 7 (29) 14 ± 7 (42) 59 0.288
Stiffness
x (% changed) 33 ± 9 22 ± 7 (33) 11 ± 6 (51)** 67 38 ± 9 26 ± 8 (32) 14 ± 7 (46) 63 0.318
Disability
x (% changed) 32 ± 4 22 ± 4 (32) 12 ± 5 (44)** 63 33 ± 6 22 ± 5 (33) 12 ± 5 (45) 64 0.200
†No significant differences between the two groups at baseline in any of the measurements.
zP-value for group by time interaction, i.e. testing whether the change from baseline to 4 weeks was different between the two groups or not.
xPercent changed from the previous time period.
*P < 0.05.
**P < 0.01 as compared with the changed from baseline to Week 2 (analysis for BNHS only).
Table 3. Comparison of other outcome measures between the groups: pain when walking on a flat surface
Baseline
† 2 weeks 4 weeks Percent changed
from baseline
to 4 weeks
Baseline 2 weeks 4 weeks Percent changed
from baseline
to 4 weeks
P-value
z
Hospital A BNHS (n ¼ 30) Counter osteophytes capsule (n ¼ 30)
Pain (VAS)
x
(% changed)
31 ± 19 24 ± 19 (23) 15 ± 19 (45)* 52 31 ± 25 21 ± 23 (32) 13 ± 17 (38) 58 0.595
Hospital B BNHS (n ¼ 30) Viartril-s (n ¼ 30)
Pain (VAS)
x
(% changed)
47 ± 10 31 ± 9 (36) 18 ± 9 (44)** 62 51 ± 14 35 ± 11 (31) 20 ± 10 (43) 61 0.536
†No significant differences between the two groups at baseline in any of the measurements.
zP-value for group by time interaction, i.e. testing whether the change from baseline to 4 weeks was different between the two groups or not.
xPercent changed from the previous time period.
*P < 0.05.
**P < 0.01 as compared with the changed from baseline to Week 2 (analysis for BNHS only).
Table 4. Comparison of other outcome measures between the groups: patient satisfaction and investigator’s assessment of treatment response
Patient satisfaction Investigator’s assessment of treatment response
BNHS (n ¼ 30) Control (n ¼ 30) P-value* BNHS (n ¼ 30) Control (n ¼ 30) P-value*
Hospital A
Poor (%) 13.3 10.0 0.095 13.3 10.0 0.830
Fair (%) 36.7 60.0 36.7 50.0
Good (%) 30.0 6.7 33.3 26.7
Excellent (%) 20.0 23.3 16.7 13.3
Hospital B
Poor (%) 0 0 0.935 0 0 0.580
Fair (%) 16.7 20.0 23.3 16.7
Good (%) 43.3 43.3 50.0 63.3
Excellent (%) 40.0 36.7 26.7 20.0
*P-values comparing BNHS and control within each hospital.
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Hospital B.
Switch Pattern
Inthetelephonesurvey,2weeksaftercompletionofthe4week
study, 61% (35/57) had decided to stay on BNHS capsule and
60% (18/30) on Viartril-s capsule, but only 48% (14/29)
preferred to stay on counter osteophytes capsule; however,
the differences were not statistically significant.
Dosage and Cost
All the 116 subjects who completed the study had a 100% dose
taking record. To be specific, 88.2 g BNHS, 147 g counter
osteophytes or 63 g Viartril-s drugs were taken by each patient
in the treatment and two control groups, respectively, during
the 4 week period. For the dosage used in this study, the cost
for BNHS was only 80% compared with counter osteophytes
capsule and 12% compared with Viartril-s.
Discussion
This study documents the benefits of treating OA of the knee
with BNHS for OA patients who were either unresponsive to
or presented with adverse events from previous NSAID ther-
apy. We found that BNHS significantly improved WOMAC
pain, stiffness and function over 4 weeks. Although lots of
reports show that Chinese herbs are potentially effective in
the treatment of OA, few of them were carried out in accord-
ance with the GCP principle. We have followed the GCP
guidelines as close as possible when conducting the study.
Previous studies have demonstrated the efficacy of the
COX-2 specific NSAIDs in the treatment of pain and inflam-
mation due to OA, as well as its efficacy profile relative to
classical (non-COX-2 specific) high-dose NSAIDs (11–14).
Other studies have demonstrated the superior safety profile
of such drugs compared with classical NSAIDs, with a particu-
lar focus on upper gastrointestinal adverse events such as per-
foration, ulcers and bleeding (15). As COX-2 specific NSAIDs
is a relatively new drug, more research, especially long-term
follow-ups and examination of adverse effects, are needed
before its efficacy is established. Hence, we have not chosen
COX-2 specific NSAIDs as the Western control medicine.
Numerous TCM methods have been used in the treatment of
OA. The most widely studied method was acupuncture, with
several studies examining the short-term and long-term effect-
iveness of the treatment in relieving clinical pain (16–18).
Nevertheless, flaws and limitations in these studies have
been reported (19). These included inadequate sessions of
treatment, failure to control concomitant therapies and no
sham, placebo or controlled group. However, scientific data
on the efficacy of herbal formulae in the treatment of OA are
rarely available. It was difficult to choose the kind of Chinese
medicine for comparison purposes. We finally decided to use a
drug that is commonly prescribed.
OA is a disease in which compliance and persistence are
known to be rather poor. In this study, the BNHS was generally
safe and well tolerated. After 4 weeks of treatment, 61% still
preferred to stay on BNHS. Compared with NSAIDs, the
anti-pain mechanism of BNHS is still unclear. The specific
way NSAIDs develop effect is through the inhibition of
COX. Meanwhile, the most common renal effects of conven-
tional NSAIDs attributable to the inhibition of COX are
a reduction in both glomerular filtration rate and excretion of
sodium, with the attendant potential for fluid retention and
edema (19). Viartril-s mainly consists of chondroitin sulfate,
which is a chondroprotection agent and a key component of
the extracellular matrix of cartilage. Studies have documented
that glucosamine is absorbed by the gastrointestinal tract with
26% bioavailability and incorporated into plasma proteins.
The supplement has anti-inflammatory properties but not anal-
gesic properties (20). A previous study showed that BNHS
could improve pain threshold of rats, and BNHS could inhibit
the expression of matrix metalloproteases-3 of chondrocyte
in vitro. BNHS is a complex formula, the effectiveness of
which appeared to be comprehensive and similar to chondro-
protection or degeneration protection (21). However, the exact
mechanism requires further investigations.
The major limitation of the present study was the lack of
a placebo group. We cannot rule out the possibility that
patients got better despite any treatments they received, espe-
cially symptoms in OA often improve with no treatment and
undergo a fluctuating course. The lack of any significant dif-
ferences across the three treatments might well be explained
by this. However, as the two comparison drugs were com-
monly prescribed in the two participating hospitals, including
a control arm with, say, paracetamol but without the chosen
control drugs would be extremely difficult for the researchers
to obtain ethical approval.
The finding that BNHS is as effective as both controlled
drugs is itself very encouraging, as it implies that the cost-
effectiveness of BNHS could be substantially higher. This is
due to the fact BNHS is 88% less expensive than the Western
drug Viartril-s. Although BNHS is only marginally cheaper
than the other Chinese herbal medicine, the dosage required
to achieve similar effects is lower (88.2 versus 147 g per
case), hence the total cost is substantially lower. It must also
be mentioned that compared with boiled herbal formula, cap-
sules are more likely to be accepted.
One limitation of this study was that sample size was not
very large. Nevertheless, the effect sizes (in terms of mean dif-
ferences between the Experimental and the Controls divided
by the standard deviations, as shown in Table 2) were fairly
small, indicating that the non-significant differences could
not be explained by sample size alone; there were in fact no
apparent differences in any of the outcome measures between
the groups. Yet, any conclusive remarks on equivalence
can only be made after a proper bioequivalence study with
a much larger sample is conducted. Another limitation was
the lack of long-term follow-up and evaluation. However, the
duration chosen in the present study was in line with acute
eCAM 2005;2(3) 367OA flare episodes, and the study was long enough to document
BNHS’s rapid onset of action and its sustained efficacy over
4 weeks. Although WOMAC is an internationally recognized
measurement method, it has never been used as an outcome
measure in clinical trials of Chinese herbs; but we do not see
why it could have caused any concerns. Given the differences
between Chinese herbs and Western medicine, it was difficult
to employ a double-blind design in Hospital B. Unfortunately,
the degree of potential bias introduced was simply not
estimable.
In conclusion, this study suggests that BNHS improves
disease-specific symptoms, such as pain, stiffness and
decreased function in patients with painful knee OA within
4 weeks, and has similar effects compared with other com-
monly prescribed Western and Chinese herbal drugs, but the
prescription costs less.
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